

315
Wakefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	26	27.5	94.6	(61.8-138.6)	Male	17	14.0	121.3	(70.6-194.2)
Female	11	11.3	97.5	(48.6-174.4)	Female	14	11.9	117.6	(64.3-197.4)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	5.2	nc	(nc-nc)	Male	6	3.8	156.5	(57.1-340.7)
Female	4	4.8	nc	(nc-nc)	Female	1	3.5	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.8	nc	(nc-nc)	Male	20	13.8	144.9	(88.5-223.8)
Female	111	112.9	98.3	(80.9-118.4)	Female	13	13.9	93.8	(49.9-160.4)
Cervix Uteri					Oral Cavity & Pharynx				
Female	8	5.2	153.8	(66.2-303.1)	Male	5	10.4	48.0	(15.5-112.1)
Colon / Rectum					Female	2	5.5	nc	(nc-nc)
Male	33	42.4	77.9	(53.6-109.4)	Ovary				
Female	51	46.7	109.2	(81.3-143.5)	Female	14	11.6	120.6	(65.9-202.4)
Esophagus					Pancreas				
Male	6	6.6	90.6	(33.1-197.2)	Male	11	7.9	139.8	(69.7-250.1)
Female	2	2.3	nc	(nc-nc)	Female	9	9.7	92.8	(42.3-176.1)
Hodgkin Lymphoma					Prostate				
Male	2	2.3	nc	(nc-nc)	Male	124	110.7	112.0	(93.2-133.5)
Female	2	2.0	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	3	7.2	nc	(nc-nc)
Male	9	10.9	82.5	(37.6-156.6)	Female	3	5.0	nc	(nc-nc)
Female	5	7.8	63.9	(20.6-149.1)	Testis				
Larynx					Male	7	4.0	174.5	(69.9-359.6)
Male	2	4.9	nc	(nc-nc)					

Female	1	1.4	nc	(nc-nc)
Leukemia				
Male	12	8.4	142.5	(73.6-249.0)
Female	10	7.8	129.0	(61.8-237.3)
Liver and Intrahepatic Bile Ducts				
Male	6	5.1	117.9	(43.1-256.7)
Female	2	2.2	nc	(nc-nc)
Lung and Bronchus				
Male	42	53.8	78.1	(56.3-105.6)
Female	46	50.9	90.5	(66.2-120.7)

Thyroid				
Male	6	2.7	225.5	(82.3-490.8)
Female	10	8.8	113.8	(54.5-209.2)
Uteri Corpus and Uterus, NOS				
Female	22	21.9	100.5	(62.9-152.1)
All Sites / Types				
Male	370	366.4	101.0	(90.9-111.8)
Female	367	375.1	97.8	(88.1-108.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

316
Wales

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	1	1.3	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	5	6.3	78.7	(25.4-183.8)	Female	1	0.6	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				

						Male	0	0.7	nc	(nc-nc)
	Female	0	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Colon / Rectum						Ovary				
	Male	2	2.2	nc	(nc-nc)					
	Female	1	1.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Esophagus						Pancreas				
	Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
	Male	0	0.2	nc	(nc-nc)	Male	10	6.3	158.3	(75.8-291.1)
	Female	0	0.1	nc	(nc-nc)					
Kidney & Renal Pelvis						Stomach				
	Male	0	0.7	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
	Female	1	0.4	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Larynx						Testis				
	Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)					
Leukemia						Thyroid				
	Male	1	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
	Female	0	0.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
	Male	1	0.3	nc	(nc-nc)					
	Female	0	0.1	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Lung and Bronchus						All Sites / Types				
	Male	5	2.8	180.9	(58.3-422.1)	Male	23	20.2	113.7	(72.1-170.6)
	Female	3	2.3	nc	(nc-nc)	Female	16	18.4	87.0	(49.7-141.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

317

Walpole

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	19	24.9	76.3	(45.9-119.2)	Male	14	13.0	107.4	(58.6-180.1)
Female	6	8.8	67.8	(24.8-147.6)	Female	11	9.9	111.6	(55.7-199.8)
Brain and Other Nervous System					Multiple Myeloma				
Male	8	5.0	160.6	(69.1-316.4)	Male	1	3.5	nc	(nc-nc)
Female	6	4.0	150.4	(54.9-327.3)	Female	7	2.8	253.9	(101.7-523.3)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.8	nc	(nc-nc)	Male	15	12.8	117.3	(65.6-193.5)
Female	113	94.7	119.3	(98.3-143.5)	Female	8	11.0	72.6	(31.3-143.0)
Cervix Uteri					Oral Cavity & Pharynx				
Female	4	4.4	nc	(nc-nc)	Male	7	9.8	71.5	(28.6-147.3)
Colon / Rectum					Female	8	4.5	176.5	(76.0-347.7)
Male	50	38.6	129.7	(96.2-170.9)	Ovary				
Female	31	35.7	86.8	(59.0-123.2)	Female	5	9.6	52.1	(16.8-121.6)
Esophagus					Pancreas				
Male	6	6.1	98.0	(35.8-213.2)	Male	3	7.2	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	8	7.4	107.7	(46.4-212.3)
Hodgkin Lymphoma					Prostate				
Male	1	2.2	nc	(nc-nc)	Male	107	102.9	104.0	(85.2-125.7)
Female	3	1.6	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	9	6.6	137.2	(62.6-260.4)
Male	5	10.2	49.2	(15.9-114.8)					

Larynx	Female	7	6.4	109.2	(43.7-224.9)	Testis	Female	3	3.8	nc	(nc-nc)
	Male	2	4.6	nc	(nc-nc)		Male	2	3.9	nc	(nc-nc)
Leukemia	Female	3	1.2	nc	(nc-nc)	Thyroid					
	Male	6	7.8	77.0	(28.1-167.7)		Male	3	2.6	nc	(nc-nc)
	Female	11	6.2	177.9	(88.7-318.3)		Female	10	7.5	134.1	(64.2-246.6)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	2	4.7	nc	(nc-nc)						
	Female	1	1.7	nc	(nc-nc)		Female	15	18.7	80.3	(44.9-132.4)
Lung and Bronchus						All Sites / Types					
	Male	54	49.2	109.7	(82.4-143.2)		Male	347	338.1	102.6	(92.1-114.0)
	Female	53	41.2	128.7	(96.4-168.3)		Female	343	304.6	112.6	(101.0-125.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

318
Waltham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	56	56.7	98.8	(74.6-128.3)	Male	25	29.8	84.0	(54.3-124.0)
Female	16	22.8	70.1	(40.0-113.8)	Female	18	25.5	70.6	(41.8-111.7)
Brain and Other Nervous System					Multiple Myeloma				
Male	16	11.5	139.7	(79.8-226.8)	Male	9	7.9	114.1	(52.1-216.7)
Female	8	10.0	80.2	(34.5-158.0)	Female	12	7.1	168.6	(87.0-294.6)
Breast					Non-Hodgkin Lymphoma				

Male	6	1.7	349.5	(127.6-760.8)	Male	28	29.5	95.0	(63.1-137.3)
Female	220	228.9	96.1	(83.8-109.7)	Female	22	28.5	77.2	(48.4-116.9)
Cervix Uteri					Oral Cavity & Pharynx				
Female	9	11.0	81.9	(37.4-155.5)	Male	28	21.4	130.8	(86.9-189.1)
Colon / Rectum					Female	8	11.4	70.2	(30.2-138.4)
Male	85	87.5	97.2	(77.6-120.2)	Ovary				
Female	92	93.5	98.4	(79.3-120.7)	Female	29	23.8	121.9	(81.6-175.0)
Esophagus					Pancreas				
Male	16	13.6	117.3	(67.0-190.6)	Male	15	16.2	92.7	(51.9-152.9)
Female	4	4.6	nc	(nc-nc)	Female	17	19.5	87.4	(50.9-139.9)
Hodgkin Lymphoma					Prostate				
Male	4	6.1	nc	(nc-nc)	Male	213	229.4	92.9	(80.8-106.2)
Female	5	5.1	98.1	(31.6-229.0)	Stomach				
Kidney & Renal Pelvis					Male	17	14.9	114.1	(66.4-182.7)
Male	10	22.5	44.5	(21.3-81.8)	Female	12	10.0	120.2	(62.0-209.9)
Female	13	16.0	81.3	(43.2-139.0)	Testis				
Larynx					Male	8	11.5	69.8	(30.1-137.5)
Male	9	10.1	89.1	(40.7-169.2)	Thyroid				
Female	3	2.8	nc	(nc-nc)	Male	6	6.1	97.6	(35.6-212.4)
Leukemia					Female	19	19.8	96.2	(57.9-150.2)
Male	17	17.8	95.4	(55.6-152.8)	Uteri Corpus and Uterus, NOS				
Female	13	15.8	82.2	(43.7-140.6)	Female	38	45.2	84.1	(59.5-115.4)
Liver and Intrahepatic Bile Ducts					All Sites / Types				
Male	8	10.4	76.9	(33.1-151.5)	Male	762	765.9	99.5	(92.6-106.8)
Female	10	4.4	226.4	(108.4-416.3)	Female	732	766.4	95.5	(88.7-102.7)
Lung and Bronchus									
Male	117	110.9	105.5	(87.2-126.4)					
Female	100	104.1	96.1	(78.2-116.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

319
Ware

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	12	10.5	114.5	(59.1-200.0)	Male	6	5.3	112.2	(41.0-244.2)
Female	6	4.3	139.7	(51.0-304.1)	Female	4	4.4	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	2.0	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.3	nc	(nc-nc)	Male	7	5.3	132.4	(53.1-272.9)
Female	25	42.2	59.3	(38.4-87.5)	Female	2	5.3	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	5	1.9	262.9	(84.7-613.6)	Male	2	4.0	nc	(nc-nc)
Colon / Rectum					Female	3	2.1	nc	(nc-nc)
Male	17	16.2	105.2	(61.2-168.4)	Ovary				
Female	14	17.8	78.5	(42.9-131.7)	Female	2	4.4	nc	(nc-nc)
Esophagus					Pancreas				
Male	1	2.5	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	1	0.9	nc	(nc-nc)	Male	49	42.3	115.7	(85.6-153.0)
Female	0	0.8	nc	(nc-nc)					

Kidney & Renal Pelvis					Stomach				
Male	2	4.2	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
Larynx					Testis				
Male	4	1.9	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)					
Leukemia					Thyroid				
Male	2	3.2	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	Female	5	3.2	154.9	(49.9-361.6)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	1	1.9	nc	(nc-nc)					
Female	4	0.8	nc	(nc-nc)	Female	13	8.2	157.7	(83.9-269.7)
Lung and Bronchus					All Sites / Types				
Male	28	20.6	136.2	(90.5-196.9)	Male	151	140.1	107.8	(91.3-126.4)
Female	20	19.4	103.0	(62.9-159.1)	Female	128	141.5	90.4	(75.4-107.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

320
Wareham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	22	24.6	89.6	(56.1-135.6)	Male	14	12.0	116.7	(63.7-195.8)
Female	5	9.2	54.3	(17.5-126.7)	Female	8	9.7	82.8	(35.7-163.2)
Brain and Other Nervous System					Multiple Myeloma				
Male	8	4.5	177.6	(76.5-350.1)	Male	2	3.4	nc	(nc-nc)

Male	72	48.1	149.7	(117.2-188.6)
Female	69	42.6	162.0	(126.1-205.1)

Male	411	325.5	126.3	(114.4-139.1)
Female	334	306.9	108.8	(97.5-121.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

321
Warren

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	6	5.1	117.6	(42.9-256.0)	Male	2	2.6	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	1.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
Female	13	18.7	69.4	(36.9-118.6)	Female	2	2.2	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	0.9	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Colon / Rectum					Female	1	0.9	nc	(nc-nc)
Male	10	7.9	126.9	(60.7-233.3)	Ovary				
Female	11	7.0	156.6	(78.1-280.2)	Female	1	1.9	nc	(nc-nc)
Esophagus					Pancreas				
Male	2	1.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)

Hodgkin Lymphoma					Prostate				
Male	0	0.4	nc	(nc-nc)	Male	21	21.4	98.3	(60.8-150.2)
Female	1	0.4	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	0	2.1	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Larynx					Testis				
Male	2	0.9	nc	(nc-nc)	Male	3	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)					
Leukemia					Thyroid				
Male	0	1.6	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	0	1.0	nc	(nc-nc)					
Female	0	0.3	nc	(nc-nc)	Female	4	3.7	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	4	10.1	nc	(nc-nc)	Male	63	69.2	91.0	(69.9-116.5)
Female	5	8.2	61.1	(19.7-142.7)	Female	59	60.5	97.5	(74.2-125.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	1	0.8	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)

Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	8	3.0	267.0	(115.0-526.2)	Female	0	0.3	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	0	1.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Pancreas				
Esophagus					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Prostate				
Hodgkin Lymphoma					Male	4	3.3	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Stomach				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Kidney & Renal Pelvis					Female	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Testis				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Larynx					Thyroid				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Leukemia					Uteri Corpus and Uterus, NOS				
Male	0	0.3	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)					

	Male	0	0.2	nc	(nc-nc)				
	Female	0	0.0	nc	(nc-nc)	Female	1	0.6	nc (nc-nc)
Lung and Bronchus						All Sites / Types			
	Male	2	1.6	nc	(nc-nc)	Male	7	11.2	62.6 (25.1-129.1)
	Female	0	1.2	nc	(nc-nc)	Female	13	9.1	142.3 (75.7-243.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

323

Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	1	0.6	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
					Female	0	0.1	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	0	1.0	nc	(nc-nc)					
Female	1	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)

Esophagus					Pancreas				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.0	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Larynx					Testis				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
Leukemia					Thyroid				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	0	0.1	nc	(nc-nc)					
Female	0	0.0	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	1	1.2	nc	(nc-nc)	Male	6	8.6	69.5	(25.4-151.3)
Female	0	0.9	nc	(nc-nc)	Female	5	7.0	71.0	(22.9-165.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	40	34.2	116.8	(83.5-159.1)	Male	13	17.2	75.4	(40.1-128.9)
Female	21	15.3	136.9	(84.7-209.2)	Female	14	16.4	85.3	(46.6-143.1)
Brain and Other Nervous System					Multiple Myeloma				
Male	6	6.4	93.9	(34.3-204.4)	Male	3	4.7	nc	(nc-nc)
Female	11	6.3	173.3	(86.4-310.2)	Female	3	4.8	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	1.0	nc	(nc-nc)	Male	15	17.1	87.7	(49.0-144.6)
Female	139	147.0	94.6	(79.5-111.7)	Female	23	18.9	121.8	(77.2-182.7)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	7.1	nc	(nc-nc)	Male	13	12.1	107.1	(57.0-183.1)
Colon / Rectum					Ovary				
Male	41	52.4	78.2	(56.1-106.1)	Female	12	15.3	78.2	(40.4-136.6)
Female	58	63.8	90.9	(69.0-117.6)	Pancreas				
Esophagus					Male	10	9.6	103.8	(49.7-190.8)
Male	8	8.0	100.3	(43.2-197.7)	Female	12	13.3	90.2	(46.6-157.6)
Female	4	3.1	nc	(nc-nc)	Prostate				
Hodgkin Lymphoma					Male	116	133.8	86.7	(71.7-104.0)
Male	3	3.2	nc	(nc-nc)	Stomach				
Female	5	3.0	164.5	(53.0-384.0)	Male	12	8.9	134.7	(69.5-235.3)
Kidney & Renal Pelvis					Female	10	6.9	144.9	(69.4-266.5)
Male	15	13.0	115.1	(64.4-189.9)	Testis				
Female	7	10.4	67.1	(26.9-138.3)	Male	5	6.2	81.2	(26.2-189.6)
Larynx					Thyroid				
Male	3	5.8	nc	(nc-nc)					
Female	4	1.8	nc	(nc-nc)					
Leukemia									

Male	8	10.4	77.2	(33.3-152.2)
Female	15	10.4	144.6	(80.9-238.6)
Liver and Intrahepatic Bile Ducts				
Male	7	6.1	115.7	(46.3-238.3)
Female	2	3.0	nc	(nc-nc)
Lung and Bronchus				
Male	64	66.3	96.6	(74.4-123.3)
Female	64	68.5	93.5	(72.0-119.4)

Male	4	3.4	nc	(nc-nc)
Female	16	12.5	128.2	(73.3-208.3)
Uteri Corpus and Uterus, NOS				
Female	38	28.5	133.2	(94.2-182.8)
All Sites / Types				
Male	417	449.8	92.7	(84.0-102.1)
Female	506	502.0	100.8	(92.2-110.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

325

Wayland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	18	15.8	113.7	(67.4-179.8)
Female	4	5.4	nc	(nc-nc)
Brain and Other Nervous System				
Male	3	3.0	nc	(nc-nc)
Female	5	2.5	202.2	(65.2-471.9)
Breast				
Male	1	0.5	nc	(nc-nc)
Female	65	61.5	105.7	(81.6-134.7)
Cervix Uteri				
Female	1	2.7	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	13	8.0	161.9	(86.1-276.9)
Female	7	6.1	114.2	(45.7-235.3)
Multiple Myeloma				
Male	2	2.2	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	12	7.9	152.7	(78.8-266.7)
Female	5	6.7	74.2	(23.9-173.2)
Oral Cavity & Pharynx				
Male	3	6.3	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)

Colon / Rectum					Ovary				
Male	21	24.5	85.6	(53.0-130.8)					
Female	23	21.3	107.8	(68.3-161.8)	Female	10	6.1	163.3	(78.2-300.3)
Esophagus					Pancreas				
Male	7	4.0	175.9	(70.5-362.5)	Male	3	4.6	nc	(nc-nc)
Female	3	1.1	nc	(nc-nc)	Female	4	4.4	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	5	1.1	451.1	(145.4-1052.8)	Male	78	68.1	114.6	(90.6-143.0)
Female	0	0.9	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	5	6.5	76.6	(24.7-178.8)	Male	3	4.1	nc	(nc-nc)
Female	3	4.0	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
Larynx					Testis				
Male	3	3.0	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)					
Leukemia					Thyroid				
Male	4	4.8	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	4	3.7	nc	(nc-nc)	Female	7	4.5	154.1	(61.8-317.6)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	3	3.0	nc	(nc-nc)					
Female	1	1.0	nc	(nc-nc)	Female	15	12.3	121.7	(68.0-200.7)
Lung and Bronchus					All Sites / Types				
Male	11	31.8	34.6	(17.2-61.8)	Male	208	216.0	96.3	(83.6-110.3)
Female	19	25.8	73.5	(44.2-114.8)	Female	195	190.9	102.1	(88.3-117.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	Male	6	3.3	179.9	(65.7-391.6)		Male	4	2.5	nc	(nc-nc)
	Female	2	0.9	nc	(nc-nc)						
Leukemia						Thyroid					
	Male	5	5.8	85.5	(27.6-199.5)		Male	2	1.7	nc	(nc-nc)
	Female	7	5.4	129.3	(51.8-266.5)		Female	2	5.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	2	3.4	nc	(nc-nc)						
	Female	1	1.6	nc	(nc-nc)		Female	18	14.5	124.4	(73.7-196.6)
Lung and Bronchus						All Sites / Types					
	Male	39	37.5	104.1	(74.0-142.3)		Male	249	252.9	98.5	(86.6-111.5)
	Female	24	35.1	68.5	(43.9-101.9)		Female	254	255.0	99.6	(87.7-112.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

327
Wellesley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI		
Bladder, Urinary					Melanoma of Skin						
	Male	19	29.5	64.3	(38.7-100.5)		Male	22	14.8	149.1	(93.4-225.7)
	Female	14	11.3	123.4	(67.4-207.1)		Female	21	12.3	170.4	(105.5-260.5)
Brain and Other Nervous System					Multiple Myeloma						
	Male	5	5.5	90.3	(29.1-210.7)		Male	2	4.1	nc	(nc-nc)
	Female	2	5.1	nc	(nc-nc)		Female	1	3.5	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma						
	Male	0	0.9	nc	(nc-nc)		Male	14	14.6	96.0	(52.4-161.1)
	Female	124	118.2	104.9	(87.3-125.1)		Female	11	14.0	78.6	(39.2-140.6)

Cervix Uteri					Oral Cavity & Pharynx					
	Female	2	5.2	nc	(nc-nc)	Male	10	11.4	87.8	(42.0-161.5)
	Female	2	5.2	nc	(nc-nc)	Female	3	5.8	nc	(nc-nc)
Colon / Rectum					Ovary					
	Male	43	45.6	94.3	(68.2-127.0)					
	Female	34	46.2	73.6	(51.0-102.8)	Female	8	12.1	65.9	(28.4-129.9)
Esophagus					Pancreas					
	Male	7	7.2	96.6	(38.7-199.0)	Male	4	8.5	nc	(nc-nc)
	Female	5	2.3	219.7	(70.8-512.8)	Female	9	9.6	93.9	(42.9-178.3)
Hodgkin Lymphoma					Prostate					
	Male	4	2.2	nc	(nc-nc)	Male	124	122.5	101.2	(84.2-120.7)
	Female	1	2.3	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach					
	Male	8	11.8	67.6	(29.1-133.2)	Male	3	7.8	nc	(nc-nc)
	Female	10	8.1	123.8	(59.3-227.7)	Female	3	4.9	nc	(nc-nc)
Larynx					Testis					
	Male	1	5.4	nc	(nc-nc)	Male	0	3.3	nc	(nc-nc)
	Female	2	1.5	nc	(nc-nc)					
Leukemia					Thyroid					
	Male	9	9.0	100.4	(45.8-190.6)	Male	3	2.7	nc	(nc-nc)
	Female	5	8.0	62.8	(20.2-146.5)	Female	6	9.2	65.4	(23.9-142.3)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS					
	Male	4	5.5	nc	(nc-nc)					
	Female	2	2.2	nc	(nc-nc)	Female	20	23.5	85.0	(51.9-131.3)
Lung and Bronchus					All Sites / Types					
	Male	29	58.1	49.9	(33.4-71.7)	Male	326	395.9	82.3	(73.6-91.8)
	Female	29	52.0	55.8	(37.4-80.2)	Female	337	385.5	87.4	(78.3-97.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);

	Male	1	1.7	nc	(nc-nc)		Male	1	1.2	nc	(nc-nc)
	Female	1	1.1	nc	(nc-nc)		Female	1	0.7	nc	(nc-nc)
Larynx						Testis					
	Male	1	0.8	nc	(nc-nc)		Male	0	0.3	nc	(nc-nc)
	Female	0	0.2	nc	(nc-nc)						
Leukemia						Thyroid					
	Male	3	1.3	nc	(nc-nc)		Male	1	0.3	nc	(nc-nc)
	Female	0	1.0	nc	(nc-nc)		Female	0	1.0	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	0	0.8	nc	(nc-nc)						
	Female	1	0.3	nc	(nc-nc)		Female	2	3.2	nc	(nc-nc)
Lung and Bronchus						All Sites / Types					
	Male	5	9.1	55.0	(17.7-128.3)		Male	69	60.0	114.9	(89.4-145.5)
	Female	9	7.4	121.5	(55.4-230.6)		Female	55	51.8	106.2	(80.0-138.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

329

Wendell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI		
Bladder, Urinary					Melanoma of Skin						
	Male	0	0.8	nc	(nc-nc)		Male	0	0.5	nc	(nc-nc)
	Female	0	0.2	nc	(nc-nc)		Female	0	0.4	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma						
	Male	0	0.2	nc	(nc-nc)		Male	0	0.1	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	0	0.1	nc	(nc-nc)

Breast						Non-Hodgkin Lymphoma					
	Male	0	0.0	nc	(nc-nc)		Male	1	0.5	nc	(nc-nc)
	Female	3	3.6	nc	(nc-nc)		Female	0	0.3	nc	(nc-nc)
Cervix Uteri						Oral Cavity & Pharynx					
	Female	0	0.2	nc	(nc-nc)		Male	0	0.4	nc	(nc-nc)
Colon / Rectum							Female	0	0.2	nc	(nc-nc)
	Male	0	1.2	nc	(nc-nc)	Ovary					
	Female	0	0.9	nc	(nc-nc)		Female	0	0.3	nc	(nc-nc)
Esophagus						Pancreas					
	Male	0	0.2	nc	(nc-nc)		Male	0	0.2	nc	(nc-nc)
	Female	0	0.0	nc	(nc-nc)		Female	1	0.2	nc	(nc-nc)
Hodgkin Lymphoma						Prostate					
	Male	0	0.1	nc	(nc-nc)		Male	0	3.4	nc	(nc-nc)
	Female	1	0.1	nc	(nc-nc)	Stomach					
Kidney & Renal Pelvis							Male	0	0.2	nc	(nc-nc)
	Male	2	0.4	nc	(nc-nc)		Female	0	0.1	nc	(nc-nc)
	Female	0	0.2	nc	(nc-nc)	Testis					
Larynx							Male	0	0.2	nc	(nc-nc)
	Male	0	0.2	nc	(nc-nc)	Thyroid					
	Female	0	0.0	nc	(nc-nc)		Male	0	0.1	nc	(nc-nc)
Leukemia							Female	0	0.4	nc	(nc-nc)
	Male	0	0.3	nc	(nc-nc)	Uteri Corpus and Uterus, NOS					
	Female	1	0.2	nc	(nc-nc)		Female	0	0.7	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						All Sites / Types					
	Male	0	0.2	nc	(nc-nc)		Male	3	11.4	nc	(nc-nc)
	Female	0	0.0	nc	(nc-nc)						
Lung and Bronchus											
	Male	0	1.5	nc	(nc-nc)						

Female	0	1.1	nc	(nc-nc)	Female	7	9.9	70.9	(28.4-146.1)
--------	---	-----	----	---------	--------	---	-----	------	--------------

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

330
Wenham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	6	5.0	119.0	(43.4-259.0)	Male	6	2.5	243.4	(88.9-529.9)
Female	1	1.8	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	0.9	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	2	0.1	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	19	18.1	105.2	(63.3-164.3)	Female	0	2.2	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.8	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Colon / Rectum					Female	0	0.9	nc	(nc-nc)
Male	4	7.7	nc	(nc-nc)	Ovary				
Female	12	7.0	170.6	(88.1-298.1)	Female	0	1.9	nc	(nc-nc)
Esophagus					Pancreas				
Male	1	1.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				

Male	0	0.4	nc	(nc-nc)	Male	19	20.4	93.0	(56.0-145.3)
Female	0	0.4	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	3	2.0	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Larynx					Testis				
Male	1	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)					
Leukemia					Thyroid				
Male	2	1.5	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	1	0.9	nc	(nc-nc)					
Female	0	0.3	nc	(nc-nc)	Female	1	3.6	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	12	9.9	121.2	(62.6-211.7)	Male	67	66.7	100.4	(77.8-127.5)
Female	5	8.2	60.9	(19.6-142.1)	Female	50	59.5	84.1	(62.4-110.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

331

West Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	9	9.1	98.5	(45.0-187.0)	Male	2	4.7	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)

Brain and Other Nervous System

Male	1	1.8	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)

Breast

Male	0	0.3	nc	(nc-nc)
Female	26	29.9	86.9	(56.8-127.4)

Cervix Uteri

Female	1	1.3	nc	(nc-nc)
--------	---	-----	----	---------

Colon / Rectum

Male	8	14.1	56.9	(24.5-112.1)
Female	8	12.2	65.8	(28.3-129.6)

Esophagus

Male	2	2.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)

Hodgkin Lymphoma

Male	2	0.9	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)

Kidney & Renal Pelvis

Male	2	3.6	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)

Larynx

Male	3	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)

Leukemia

Male	2	2.8	nc	(nc-nc)
Female	4	2.0	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	0	1.7	nc	(nc-nc)
------	---	-----	----	---------

Multiple Myeloma

Male	0	1.3	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)

Non-Hodgkin Lymphoma

Male	2	4.7	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)

Oral Cavity & Pharynx

Male	3	3.4	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)

Ovary

Female	2	3.1	nc	(nc-nc)
--------	---	-----	----	---------

Pancreas

Male	2	2.6	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)

Prostate

Male	36	35.8	100.6	(70.4-139.3)
------	----	------	-------	--------------

Stomach

Male	1	2.4	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)

Testis

Male	1	1.6	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	0	0.9	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	0	0.6	nc	(nc-nc)	Female	5	5.9	85.1	(27.4-198.6)
Lung and Bronchus					All Sites / Types				
Male	8	17.7	45.1	(19.4-88.9)	Male	90	121.3	74.2	(59.7-91.2)
Female	12	13.7	87.7	(45.3-153.2)	Female	84	98.5	85.3	(68.0-105.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

332

West Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	7	8.4	83.1	(33.3-171.2)	Male	8	4.1	193.7	(83.4-381.6)
Female	8	3.3	246.0	(105.9-484.8)	Female	2	3.3	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	1.5	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)	Male	6	4.1	146.3	(53.4-318.6)
Female	30	32.1	93.6	(63.1-133.6)	Female	2	3.9	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	1.4	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
					Female	2	1.6	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	11	12.9	85.1	(42.4-152.2)	Female	1	3.3	nc	(nc-nc)
Female	18	13.4	134.1	(79.4-211.9)	Pancreas				
Esophagus									

	Male	2	2.0	nc	(nc-nc)		Male	3	2.4	nc	(nc-nc)
	Female	0	0.7	nc	(nc-nc)		Female	0	2.8	nc	(nc-nc)
Hodgkin Lymphoma						Prostate					
	Male	0	0.6	nc	(nc-nc)		Male	32	33.8	94.8	(64.8-133.8)
	Female	1	0.5	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach					
	Male	4	3.3	nc	(nc-nc)		Male	1	2.2	nc	(nc-nc)
	Female	1	2.2	nc	(nc-nc)		Female	2	1.4	nc	(nc-nc)
Larynx						Testis					
	Male	2	1.5	nc	(nc-nc)		Male	1	1.0	nc	(nc-nc)
	Female	0	0.4	nc	(nc-nc)						
Leukemia						Thyroid					
	Male	2	2.5	nc	(nc-nc)		Male	0	0.7	nc	(nc-nc)
	Female	2	2.2	nc	(nc-nc)		Female	3	2.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	0	1.5	nc	(nc-nc)						
	Female	0	0.6	nc	(nc-nc)		Female	6	6.3	94.6	(34.5-205.9)
Lung and Bronchus						All Sites / Types					
	Male	22	16.4	134.2	(84.1-203.2)		Male	116	110.8	104.7	(86.5-125.6)
	Female	22	14.7	149.4	(93.6-226.2)		Female	113	106.7	105.9	(87.2-127.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bladder, Urinary						Melanoma of Skin					
Male	5	4.8	104.1	(33.6-243.0)		Male	0	2.3	nc	(nc-nc)	
Female	2	2.3	nc	(nc-nc)		Female	2	2.0	nc	(nc-nc)	
Brain and Other Nervous System						Multiple Myeloma					
Male	1	0.8	nc	(nc-nc)		Male	0	0.7	nc	(nc-nc)	
Female	1	0.8	nc	(nc-nc)		Female	0	0.7	nc	(nc-nc)	
Breast						Non-Hodgkin Lymphoma					
Male	0	0.1	nc	(nc-nc)		Male	4	2.3	nc	(nc-nc)	
Female	13	20.0	65.0	(34.6-111.2)		Female	0	2.6	nc	(nc-nc)	
Cervix Uteri						Oral Cavity & Pharynx					
Female	1	0.8	nc	(nc-nc)		Male	1	1.7	nc	(nc-nc)	
Colon / Rectum						Ovary					
Male	5	7.3	68.1	(21.9-158.9)		Female	2	2.1	nc	(nc-nc)	
Female	10	9.8	101.7	(48.7-187.1)		Pancreas					
Esophagus						Male	2	1.4	nc	(nc-nc)	
Male	0	1.1	nc	(nc-nc)		Female	3	2.0	nc	(nc-nc)	
Female	0	0.5	nc	(nc-nc)		Prostate					
Hodgkin Lymphoma						Male	16	18.2	87.9	(50.2-142.7)	
Male	0	0.3	nc	(nc-nc)		Stomach					
Female	0	0.3	nc	(nc-nc)		Male	0	1.3	nc	(nc-nc)	
Kidney & Renal Pelvis						Female	0	1.1	nc	(nc-nc)	
Male	1	1.8	nc	(nc-nc)		Testis					
Female	3	1.4	nc	(nc-nc)		Male	0	0.5	nc	(nc-nc)	
Larynx						Thyroid					
Male	1	0.8	nc	(nc-nc)		Male	0	0.4	nc	(nc-nc)	
Female	0	0.2	nc	(nc-nc)							
Leukemia											
Male	0	1.4	nc	(nc-nc)							

Female	1	1.5	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	0	0.8	nc	(nc-nc)					
Female	1	0.5	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	8	8.9	89.6	(38.6-176.6)	Male	49	61.2	80.1	(59.2-105.9)
Female	6	9.3	64.8	(23.7-141.0)	Female	51	70.0	72.9	(54.3-95.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

334

West Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	4	3.6	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	18	16.0	112.5	(66.6-177.8)	Female	1	1.6	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	2	0.8	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
					Female	0	0.7	nc	(nc-nc)
Colon / Rectum					Ovary				

	Male	5	5.8	86.1	(27.7-200.9)						
	Female	2	4.7	nc	(nc-nc)		Female	3	1.6	nc	(nc-nc)
Esophagus						Pancreas					
	Male	2	1.0	nc	(nc-nc)		Male	0	1.1	nc	(nc-nc)
	Female	1	0.2	nc	(nc-nc)		Female	1	1.0	nc	(nc-nc)
Hodgkin Lymphoma						Prostate					
	Male	0	0.3	nc	(nc-nc)		Male	21	16.4	128.3	(79.4-196.1)
	Female	0	0.3	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach					
	Male	0	1.7	nc	(nc-nc)		Male	0	1.0	nc	(nc-nc)
	Female	1	1.0	nc	(nc-nc)		Female	0	0.5	nc	(nc-nc)
Larynx						Testis					
	Male	0	0.8	nc	(nc-nc)		Male	1	0.6	nc	(nc-nc)
	Female	0	0.2	nc	(nc-nc)						
Leukemia						Thyroid					
	Male	2	1.2	nc	(nc-nc)		Male	1	0.4	nc	(nc-nc)
	Female	2	0.9	nc	(nc-nc)		Female	1	1.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	0	0.8	nc	(nc-nc)						
	Female	0	0.2	nc	(nc-nc)		Female	1	3.1	nc	(nc-nc)
Lung and Bronchus						All Sites / Types					
	Male	7	7.4	94.6	(37.9-194.9)		Male	49	52.9	92.6	(68.5-122.5)
	Female	7	5.9	118.8	(47.6-244.8)		Female	49	47.0	104.3	(77.2-137.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	40	33.5	119.5	(85.3-162.7)	Male	11	16.5	66.6	(33.2-119.2)
Female	17	12.5	135.8	(79.1-217.5)	Female	11	13.0	84.3	(42.0-150.9)
Brain and Other Nervous System					Multiple Myeloma				
Male	7	6.2	113.4	(45.4-233.6)	Male	2	4.6	nc	(nc-nc)
Female	1	5.3	nc	(nc-nc)	Female	1	3.9	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	1.0	nc	(nc-nc)	Male	9	16.4	54.8	(25.0-104.0)
Female	113	124.9	90.4	(74.5-108.7)	Female	15	15.4	97.6	(54.6-161.0)
Cervix Uteri					Oral Cavity & Pharynx				
Female	3	5.6	nc	(nc-nc)	Male	15	12.2	122.8	(68.7-202.5)
Colon / Rectum					Female	6	6.1	97.7	(35.7-212.7)
Male	52	51.4	101.2	(75.6-132.7)	Ovary				
Female	49	51.2	95.7	(70.8-126.5)	Female	8	12.9	62.2	(26.8-122.6)
Esophagus					Pancreas				
Male	8	8.0	100.2	(43.2-197.5)	Male	10	9.5	105.2	(50.3-193.4)
Female	6	2.5	239.6	(87.5-521.5)	Female	9	10.7	84.3	(38.5-160.1)
Hodgkin Lymphoma					Prostate				
Male	4	2.6	nc	(nc-nc)	Male	105	135.5	77.5	(63.4-93.8)
Female	1	2.2	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	8	8.7	92.1	(39.6-181.4)
Male	11	13.0	84.8	(42.3-151.8)	Female	5	5.4	92.4	(29.8-215.6)
Female	8	8.8	91.3	(39.3-179.9)	Testis				
Larynx					Male	4	4.5	nc	(nc-nc)
Male	6	5.9	101.9	(37.2-221.8)					

Female	1	1.6	nc	(nc-nc)
Leukemia				
Male	8	10.1	79.5	(34.2-156.7)
Female	3	8.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	5	6.0	82.9	(26.7-193.4)
Female	3	2.4	nc	(nc-nc)
Lung and Bronchus				
Male	63	65.6	96.1	(73.8-122.9)
Female	62	57.6	107.7	(82.6-138.1)

Thyroid				
Male	4	3.1	nc	(nc-nc)
Female	8	9.5	84.2	(36.2-165.8)
Uteri Corpus and Uterus, NOS				
Female	29	24.8	117.2	(78.5-168.3)
All Sites / Types				
Male	402	443.1	90.7	(82.1-100.0)
Female	395	415.5	95.1	(85.9-104.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

336

West Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	3	2.1	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	4	7.3	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				

						Male	1	0.8	nc	(nc-nc)
	Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Colon / Rectum						Ovary				
	Male	2	3.2	nc	(nc-nc)					
	Female	2	2.7	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Esophagus						Pancreas				
	Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
	Male	0	0.1	nc	(nc-nc)	Male	5	8.1	61.4	(19.8-143.2)
	Female	0	0.1	nc	(nc-nc)					
Kidney & Renal Pelvis						Stomach				
	Male	0	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
	Female	1	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Larynx						Testis				
	Male	0	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)					
Leukemia						Thyroid				
	Male	0	0.6	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
	Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
	Male	0	0.4	nc	(nc-nc)					
	Female	0	0.1	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
Lung and Bronchus						All Sites / Types				
	Male	5	4.0	123.6	(39.8-288.5)	Male	21	27.1	77.4	(47.9-118.3)
	Female	6	3.2	185.1	(67.6-403.0)	Female	20	23.3	85.7	(52.3-132.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

337

West Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	4	2.3	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	13	9.9	131.9	(70.2-225.6)	Female	0	1.0	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.5	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Colon / Rectum					Female	1	0.4	nc	(nc-nc)
Male	2	3.7	nc	(nc-nc)	Ovary				
Female	4	3.0	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.2	nc	(nc-nc)	Male	17	9.6	176.4	(102.7-282.5)
Female	0	0.2	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	0	0.6	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)					

Larynx	Female	0	0.6	nc	(nc-nc)	Testis	Female	0	0.3	nc	(nc-nc)
	Male	0	0.5	nc	(nc-nc)		Male	1	0.3	nc	(nc-nc)
Leukemia	Female	0	0.1	nc	(nc-nc)	Thyroid					
	Male	0	0.8	nc	(nc-nc)		Male	1	0.3	nc	(nc-nc)
	Female	2	0.6	nc	(nc-nc)		Female	1	0.8	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	0	0.5	nc	(nc-nc)						
	Female	0	0.1	nc	(nc-nc)		Female	1	1.9	nc	(nc-nc)
Lung and Bronchus						All Sites / Types					
	Male	3	4.6	nc	(nc-nc)		Male	32	32.3	99.1	(67.8-139.9)
	Female	3	3.7	nc	(nc-nc)		Female	30	29.2	102.8	(69.4-146.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

338

Westborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	17	16.0	106.3	(61.9-170.2)	Male	7	8.8	79.5	(31.9-163.8)
Female	3	6.2	nc	(nc-nc)	Female	8	7.3	110.2	(47.4-217.1)
Brain and Other Nervous System					Multiple Myeloma				
Male	4	3.4	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				

Male	1	0.5	nc	(nc-nc)	Male	6	8.6	69.9	(25.5-152.1)
Female	75	66.6	112.6	(88.6-141.2)	Female	8	7.8	103.2	(44.4-203.4)
Cervix Uteri					Oral Cavity & Pharynx				
Female	2	3.3	nc	(nc-nc)	Male	1	6.6	nc	(nc-nc)
Colon / Rectum					Female	4	3.2	nc	(nc-nc)
Male	15	24.9	60.1	(33.6-99.2)	Ovary				
Female	21	25.6	82.0	(50.7-125.3)	Female	9	6.8	132.7	(60.6-251.9)
Esophagus					Pancreas				
Male	2	3.9	nc	(nc-nc)	Male	3	4.7	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	1	5.3	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	3	1.6	nc	(nc-nc)	Male	58	64.0	90.6	(68.8-117.2)
Female	1	1.3	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	2	4.3	nc	(nc-nc)
Male	5	6.7	74.9	(24.1-174.8)	Female	1	2.8	nc	(nc-nc)
Female	1	4.4	nc	(nc-nc)	Testis				
Larynx					Male	3	2.9	nc	(nc-nc)
Male	4	2.9	nc	(nc-nc)	Thyroid				
Female	0	0.8	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Leukemia					Female	1	5.8	nc	(nc-nc)
Male	3	5.3	nc	(nc-nc)	Uteri Corpus and Uterus, NOS				
Female	4	4.5	nc	(nc-nc)	Female	12	12.6	95.5	(49.3-166.8)
Liver and Intrahepatic Bile Ducts					All Sites / Types				
Male	2	3.1	nc	(nc-nc)	Male	172	218.0	78.9	(67.6-91.6)
Female	0	1.2	nc	(nc-nc)	Female	203	214.5	94.6	(82.1-108.6)
Lung and Bronchus									
Male	22	31.0	71.1	(44.5-107.6)					
Female	29	27.3	106.3	(71.2-152.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

339
Westfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	51	42.4	120.2	(89.5-158.0)	Male	18	21.4	84.1	(49.8-132.9)
Female	24	16.3	147.4	(94.4-219.3)	Female	17	17.5	97.2	(56.6-155.7)
Brain and Other Nervous System					Multiple Myeloma				
Male	8	8.2	98.1	(42.3-193.4)	Male	9	5.9	152.9	(69.8-290.3)
Female	6	7.1	84.2	(30.8-183.4)	Female	1	5.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	3	1.3	nc	(nc-nc)	Male	26	21.3	121.9	(79.6-178.7)
Female	157	164.1	95.7	(81.3-111.9)	Female	20	20.2	99.2	(60.6-153.2)
Cervix Uteri					Oral Cavity & Pharynx				
Female	2	7.5	nc	(nc-nc)	Male	15	15.8	94.9	(53.1-156.6)
Colon / Rectum					Female	8	8.0	99.4	(42.8-195.9)
Male	64	65.2	98.1	(75.6-125.3)	Ovary				
Female	73	67.2	108.6	(85.1-136.6)	Female	12	17.0	70.7	(36.5-123.6)
Esophagus					Pancreas				
Male	9	10.1	89.2	(40.7-169.3)	Male	17	12.1	140.3	(81.7-224.6)
Female	5	3.3	152.2	(49.0-355.2)	Female	16	14.0	114.7	(65.5-186.3)
Hodgkin Lymphoma					Prostate				
Male	0	3.7	nc	(nc-nc)	Male	133	167.6	79.4	(66.5-94.1)
Female	4	3.3	nc	(nc-nc)					

Kidney & Renal Pelvis					Stomach				
Male	19	16.6	114.5	(68.9-178.9)	Male	6	11.1	53.9	(19.7-117.4)
Female	12	11.4	105.3	(54.4-184.0)	Female	4	7.2	nc	(nc-nc)
Larynx					Testis				
Male	4	7.5	nc	(nc-nc)	Male	7	6.3	111.5	(44.7-229.8)
Female	1	2.0	nc	(nc-nc)					
Leukemia					Thyroid				
Male	7	13.1	53.3	(21.4-109.9)	Male	1	4.0	nc	(nc-nc)
Female	7	11.4	61.6	(24.7-126.9)	Female	12	13.1	91.5	(47.2-159.9)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	7	7.7	90.6	(36.3-186.7)					
Female	3	3.2	nc	(nc-nc)	Female	28	32.1	87.3	(58.0-126.1)
Lung and Bronchus					All Sites / Types				
Male	85	82.2	103.4	(82.6-127.8)	Male	515	560.8	91.8	(84.1-100.1)
Female	70	73.8	94.8	(73.9-119.8)	Female	515	545.4	94.4	(86.4-102.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

340
Westford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	18	14.9	120.7	(71.5-190.8)	Male	7	9.3	75.3	(30.2-155.1)
Female	6	5.2	115.3	(42.1-251.0)	Female	12	7.6	157.0	(81.0-274.2)
Brain and Other Nervous System					Multiple Myeloma				
Male	4	3.9	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)

Male	24	30.6	78.3	(50.2-116.5)
Female	29	25.2	115.3	(77.2-165.5)

Male	218	222.7	97.9	(85.3-111.8)
Female	246	206.7	119.0	(104.6-134.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

341
Westhampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	2	1.4	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	11	5.8	188.2	(93.8-336.8)	Female	0	0.6	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.3	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Colon / Rectum					Female	1	0.3	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	Ovary				
Female	2	1.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)

Hodgkin Lymphoma					Prostate				
Male	0	0.1	nc	(nc-nc)	Male	4	6.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	0	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Larynx					Testis				
Male	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
Leukemia					Thyroid				
Male	0	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	0	0.3	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	4	2.8	nc	(nc-nc)	Male	17	19.8	85.9	(50.0-137.5)
Female	1	2.1	nc	(nc-nc)	Female	18	16.9	106.4	(63.0-168.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

342
Westminster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	6	6.7	88.9	(32.5-193.6)	Male	0	3.8	nc	(nc-nc)

Female	0	2.3	nc	(nc-nc)	Female	5	2.9	172.8	(55.7-403.3)	
Brain and Other Nervous System					Multiple Myeloma					
Male	1	1.4	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)	
Female	0	1.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)	
Breast					Non-Hodgkin Lymphoma					
Male	0	0.2	nc	(nc-nc)	Male	0	3.6	nc	(nc-nc)	
Female	22	27.4	80.2	(50.3-121.5)	Female	0	3.0	nc	(nc-nc)	
Cervix Uteri					Oral Cavity & Pharynx					
Female	1	1.3	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)	
Colon / Rectum					Ovary					
Male	16	10.6	151.0	(86.2-245.2)	Female	6	2.7	220.1	(80.4-479.1)	
Female	6	9.1	66.1	(24.1-143.8)	Pancreas					
Esophagus					Male	0	2.0	nc	(nc-nc)	
Male	2	1.7	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)	
Female	0	0.4	nc	(nc-nc)	Prostate					
Hodgkin Lymphoma					Male	31	28.3	109.5	(74.4-155.4)	
Male	0	0.6	nc	(nc-nc)	Stomach					
Female	0	0.5	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)	
Kidney & Renal Pelvis					Female	1	0.9	nc	(nc-nc)	
Male	3	2.9	nc	(nc-nc)	Testis					
Female	2	1.7	nc	(nc-nc)	Male	6	1.1	567.1	(207.1-1234.4)	
Larynx					Thyroid					
Male	3	1.3	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)	
Female	0	0.3	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)	
Leukemia					Uteri Corpus and Uterus, NOS					
Male	2	2.2	nc	(nc-nc)						
Female	1	1.6	nc	(nc-nc)						
Liver and Intrahepatic Bile Ducts										

Male	1	1.4	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)	Female	8	5.3	151.6	(65.3-298.7)
Lung and Bronchus					All Sites / Types				
Male	5	13.4	37.3	(12.0-87.0)	Male	86	94.0	91.5	(73.2-113.0)
Female	6	10.8	55.3	(20.2-120.5)	Female	71	83.9	84.7	(66.1-106.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

343
Weston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	11	15.7	70.1	(35.0-125.5)	Male	11	7.5	146.9	(73.2-262.9)
Female	2	5.2	nc	(nc-nc)	Female	9	5.4	167.2	(76.3-317.4)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	2.7	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	5	2.2	225.1	(72.5-525.3)	Female	1	1.6	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.5	nc	(nc-nc)	Male	13	7.4	174.9	(93.1-299.2)
Female	69	54.0	127.7	(99.4-161.6)	Female	3	6.3	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	2.3	nc	(nc-nc)	Male	1	5.9	nc	(nc-nc)
					Female	1	2.6	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	26	24.1	107.8	(70.4-158.0)					
Female	16	21.2	75.6	(43.2-122.7)	Female	7	5.5	127.0	(50.9-261.7)

Esophagus					Pancreas				
Male	1	3.8	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	5	4.4	113.7	(36.6-265.3)
Hodgkin Lymphoma					Prostate				
Male	1	0.9	nc	(nc-nc)	Male	75	64.9	115.6	(90.9-144.8)
Female	1	0.9	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	3	6.1	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
Female	1	3.7	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
Larynx					Testis				
Male	1	2.8	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)					
Leukemia					Thyroid				
Male	5	4.5	110.0	(35.4-256.6)	Male	3	1.3	nc	(nc-nc)
Female	8	3.6	224.8	(96.8-442.9)	Female	11	3.8	288.8	(144.0-516.8)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	5	2.8	176.5	(56.9-411.8)					
Female	0	1.0	nc	(nc-nc)	Female	9	10.8	83.1	(37.9-157.7)
Lung and Bronchus					All Sites / Types				
Male	15	30.6	49.0	(27.4-80.8)	Male	202	206.9	97.6	(84.6-112.1)
Female	20	23.6	84.7	(51.7-130.9)	Female	182	174.9	104.1	(89.5-120.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Male	10	5.4	185.6	(88.9-341.3)
Female	5	4.1	121.1	(39.0-282.5)
Liver and Intrahepatic Bile Ducts				
Male	0	3.4	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)
Lung and Bronchus				
Male	45	35.8	125.7	(91.7-168.2)
Female	28	29.1	96.1	(63.9-138.9)

Male	0	1.7	nc	(nc-nc)
Female	8	5.1	157.7	(67.9-310.7)
Uteri Corpus and Uterus, NOS				
Female	11	13.5	81.5	(40.6-145.8)
All Sites / Types				
Male	262	244.3	107.2	(94.7-121.1)
Female	212	212.9	99.6	(86.6-113.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

345
Westwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	19	18.9	100.7	(60.6-157.2)
Female	2	7.0	nc	(nc-nc)
Brain and Other Nervous System				
Male	4	3.3	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)
Breast				
Male	0	0.5	nc	(nc-nc)
Female	82	68.6	119.5	(95.1-148.4)
Cervix Uteri				
Female	2	2.9	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	5	8.9	56.0	(18.0-130.7)
Female	10	6.9	145.4	(69.6-267.5)
Multiple Myeloma				
Male	2	2.6	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	7	8.9	78.4	(31.4-161.5)
Female	7	8.5	82.7	(33.1-170.3)
Oral Cavity & Pharynx				
Male	7	6.7	104.5	(41.9-215.4)
Female	2	3.4	nc	(nc-nc)

Colon / Rectum					Ovary				
Male	30	28.8	104.0	(70.2-148.5)					
Female	36	29.2	123.3	(86.3-170.7)	Female	3	7.1	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	4.4	nc	(nc-nc)	Male	4	5.3	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	Female	13	6.1	214.1	(113.9-366.1)
Hodgkin Lymphoma					Prostate				
Male	2	1.2	nc	(nc-nc)	Male	85	74.6	113.9	(91.0-140.8)
Female	0	1.0	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	4	7.1	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
Female	12	4.8	248.5	(128.3-434.2)	Female	2	3.1	nc	(nc-nc)
Larynx					Testis				
Male	3	3.3	nc	(nc-nc)	Male	5	1.9	262.1	(84.5-611.6)
Female	0	0.9	nc	(nc-nc)					
Leukemia					Thyroid				
Male	8	5.5	144.8	(62.3-285.3)	Male	2	1.5	nc	(nc-nc)
Female	4	4.7	nc	(nc-nc)	Female	5	4.7	105.4	(34.0-246.0)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	3	3.3	nc	(nc-nc)					
Female	0	1.4	nc	(nc-nc)	Female	10	13.5	73.9	(35.4-135.9)
Lung and Bronchus					All Sites / Types				
Male	30	36.4	82.4	(55.6-117.6)	Male	243	244.4	99.4	(87.3-112.7)
Female	30	31.7	94.6	(63.8-135.1)	Female	247	229.5	107.6	(94.6-121.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Male	8	10.5	76.5	(32.9-150.7)
Female	2	3.0	nc	(nc-nc)
Leukemia				
Male	23	17.8	129.1	(81.8-193.7)
Female	19	16.2	117.2	(70.5-183.0)
Liver and Intrahepatic Bile Ducts				
Male	10	10.7	93.4	(44.7-171.7)
Female	7	4.6	153.5	(61.5-316.3)
Lung and Bronchus				
Male	144	114.6	125.6	(106.0-147.9)
Female	134	110.0	121.8	(102.0-144.2)

Male	8	8.8	90.5	(39.0-178.3)
Thyroid				
Male	7	5.7	122.4	(49.0-252.2)
Female	23	19.1	120.4	(76.3-180.7)
Uteri Corpus and Uterus, NOS				
Female	47	48.0	98.0	(72.0-130.3)
All Sites / Types				
Male	837	780.5	107.2	(100.1-114.8)
Female	825	799.4	103.2	(96.3-110.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

347
Whately

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	0	1.8	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	5	6.5	76.5	(24.7-178.6)	Female	0	0.7	nc	(nc-nc)

Cervix Uteri						Oral Cavity & Pharynx				
	Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
	Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Colon / Rectum						Ovary				
	Male	4	2.8	nc	(nc-nc)					
	Female	4	2.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Esophagus						Pancreas				
	Male	0	0.4	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
	Male	0	0.1	nc	(nc-nc)	Male	7	7.1	98.4	(39.4-202.7)
	Female	1	0.1	nc	(nc-nc)					
Kidney & Renal Pelvis						Stomach				
	Male	1	0.7	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
	Female	0	0.4	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Larynx						Testis				
	Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)					
Leukemia						Thyroid				
	Male	0	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
	Female	0	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
	Male	0	0.3	nc	(nc-nc)					
	Female	0	0.1	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Lung and Bronchus						All Sites / Types				
	Male	2	3.4	nc	(nc-nc)	Male	21	23.7	88.5	(54.8-135.3)
	Female	0	2.7	nc	(nc-nc)	Female	16	20.4	78.4	(44.8-127.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);

	Male	1	4.8	nc	(nc-nc)		Male	2	3.0	nc	(nc-nc)
	Female	3	3.2	nc	(nc-nc)		Female	1	1.8	nc	(nc-nc)
Larynx						Testis					
	Male	6	2.1	282.8	(103.3-615.5)		Male	3	2.3	nc	(nc-nc)
	Female	0	0.6	nc	(nc-nc)						
Leukemia						Thyroid					
	Male	2	3.7	nc	(nc-nc)		Male	1	1.3	nc	(nc-nc)
	Female	4	3.2	nc	(nc-nc)		Female	10	4.5	221.8	(106.2-407.9)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	1	2.2	nc	(nc-nc)						
	Female	0	0.8	nc	(nc-nc)		Female	8	9.4	85.3	(36.7-168.1)
Lung and Bronchus						All Sites / Types					
	Male	25	21.9	114.1	(73.8-168.5)		Male	149	155.3	95.9	(81.2-112.6)
	Female	24	19.7	121.9	(78.1-181.3)		Female	186	153.4	121.2	(104.4-140.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

349

Wilbraham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI		
Bladder, Urinary					Melanoma of Skin						
	Male	15	17.9	83.9	(46.9-138.3)		Male	8	8.8	91.3	(39.3-179.9)
	Female	3	6.3	nc	(nc-nc)		Female	5	6.6	76.1	(24.5-177.7)
Brain and Other Nervous System					Multiple Myeloma						
	Male	5	3.2	155.2	(50.0-362.2)		Male	2	2.5	nc	(nc-nc)
	Female	6	2.7	225.3	(82.3-490.4)		Female	1	2.0	nc	(nc-nc)

Breast						Non-Hodgkin Lymphoma				
Male	1	0.5	nc	(nc-nc)		Male	8	8.7	92.1	(39.6-181.4)
Female	67	66.0	101.5	(78.6-128.9)		Female	10	7.7	130.0	(62.3-239.2)
Cervix Uteri						Oral Cavity & Pharynx				
						Male	2	6.8	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)		Female	3	3.2	nc	(nc-nc)
Colon / Rectum						Ovary				
Male	28	27.5	101.6	(67.5-146.9)						
Female	25	25.5	98.1	(63.5-144.8)		Female	8	6.7	119.8	(51.6-236.0)
Esophagus						Pancreas				
Male	3	4.4	nc	(nc-nc)		Male	2	5.1	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)		Female	1	5.3	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
Male	0	1.2	nc	(nc-nc)		Male	86	74.4	115.6	(92.5-142.8)
Female	2	1.0	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	2	7.1	nc	(nc-nc)		Male	6	4.6	129.4	(47.2-281.6)
Female	4	4.5	nc	(nc-nc)		Female	1	2.7	nc	(nc-nc)
Larynx						Testis				
Male	3	3.3	nc	(nc-nc)		Male	1	1.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)						
Leukemia						Thyroid				
Male	4	5.3	nc	(nc-nc)		Male	2	1.5	nc	(nc-nc)
Female	1	4.2	nc	(nc-nc)		Female	2	4.7	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	1	3.3	nc	(nc-nc)						
Female	2	1.2	nc	(nc-nc)		Female	10	13.1	76.1	(36.4-140.0)
Lung and Bronchus						All Sites / Types				
Male	16	35.4	45.1	(25.8-73.3)		Male	209	238.5	87.6	(76.2-100.4)

Female 14 29.3 47.8 (26.1-80.2)

Female 179 212.8 84.1 (72.3-97.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

350
Williamsburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	5	2.8	178.8	(57.6-417.3)	Male	2	1.5	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	4	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
Female	17	11.2	151.8	(88.4-243.1)	Female	0	1.2	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Colon / Rectum					Female	0	0.5	nc	(nc-nc)
Male	9	4.3	207.2	(94.6-393.4)	Ovary				
Female	2	3.8	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Esophagus					Pancreas				
Male	2	0.7	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				

Male	0	0.2	nc	(nc-nc)	Male	17	11.4	148.6	(86.5-237.9)
Female	0	0.2	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	0	1.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Larynx					Testis				
Male	3	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
Leukemia					Thyroid				
Male	1	0.9	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	1	0.5	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	2	5.5	nc	(nc-nc)	Male	51	37.8	134.8	(100.4-177.3)
Female	3	4.5	nc	(nc-nc)	Female	35	34.6	101.3	(70.5-140.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

351

Williamstown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	9	10.9	82.5	(37.6-156.5)	Male	1	4.9	nc	(nc-nc)
Female	3	4.6	nc	(nc-nc)	Female	6	4.1	145.8	(53.2-317.4)

Brain and Other Nervous System						Multiple Myeloma				
Male	1	1.8	nc	(nc-nc)		Male	2	1.5	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)		Female	1	1.4	nc	(nc-nc)
Breast						Non-Hodgkin Lymphoma				
Male	0	0.3	nc	(nc-nc)		Male	5	5.1	98.1	(31.6-229.0)
Female	55	40.6	135.4	(102.0-176.2)		Female	4	5.4	nc	(nc-nc)
Cervix Uteri						Oral Cavity & Pharynx				
Female	0	1.6	nc	(nc-nc)		Male	1	3.6	nc	(nc-nc)
Colon / Rectum						Ovary				
Male	16	16.5	96.8	(55.3-157.3)		Female	1	4.3	nc	(nc-nc)
Female	25	19.8	126.5	(81.9-186.8)		Pancreas				
Esophagus						Prostate				
Male	3	2.5	nc	(nc-nc)		Male	1	3.1	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)		Female	2	4.1	nc	(nc-nc)
Hodgkin Lymphoma						Stomach				
Male	0	0.9	nc	(nc-nc)		Male	5	2.9	174.7	(56.3-407.8)
Female	0	0.8	nc	(nc-nc)		Female	1	2.2	nc	(nc-nc)
Kidney & Renal Pelvis						Testis				
Male	3	3.9	nc	(nc-nc)		Male	1	1.2	nc	(nc-nc)
Female	4	3.0	nc	(nc-nc)		Thyroid				
Larynx						Uteri Corpus and Uterus, NOS				
Male	2	1.8	nc	(nc-nc)		Male	0	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)		Female	1	2.7	nc	(nc-nc)
Leukemia										
Male	5	3.1	160.0	(51.6-373.5)						
Female	2	3.1	nc	(nc-nc)						
Liver and Intrahepatic Bile Ducts										
Male	0	1.8	nc	(nc-nc)						

Female	1	0.9	nc	(nc-nc)	Female	8	8.1	99.3	(42.8-195.8)
Lung and Bronchus					All Sites / Types				
Male	10	20.6	48.6	(23.3-89.3)	Male	136	137.9	98.6	(82.7-116.7)
Female	15	19.8	75.7	(42.3-124.8)	Female	138	143.4	96.2	(80.8-113.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

352
Wilmington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	18	18.1	99.5	(58.9-157.2)	Male	10	10.3	97.3	(46.6-179.0)
Female	8	6.6	121.3	(52.2-239.0)	Female	11	8.4	131.1	(65.3-234.5)
Brain and Other Nervous System					Multiple Myeloma				
Male	5	4.1	120.7	(38.9-281.7)	Male	0	2.6	nc	(nc-nc)
Female	4	3.3	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.6	nc	(nc-nc)	Male	7	9.9	70.5	(28.2-145.3)
Female	84	77.1	108.9	(86.8-134.8)	Female	6	8.6	69.9	(25.5-152.1)
Cervix Uteri					Oral Cavity & Pharynx				
Female	3	3.9	nc	(nc-nc)	Male	8	7.9	101.5	(43.7-199.9)
					Female	3	3.6	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	28	28.5	98.4	(65.4-142.2)					
Female	26	26.2	99.3	(64.9-145.6)	Female	10	7.7	129.2	(61.8-237.6)
Esophagus					Pancreas				

Male	4	4.7	nc	(nc-nc)	Male	5	5.4	93.4	(30.1-218.0)
Female	1	1.3	nc	(nc-nc)	Female	6	5.4	111.0	(40.5-241.5)
Hodgkin Lymphoma					Prostate				
Male	2	1.9	nc	(nc-nc)	Male	96	80.1	119.9	(97.1-146.4)
Female	3	1.5	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	4	4.8	nc	(nc-nc)
Male	7	8.0	87.3	(35.0-179.8)	Female	4	2.7	nc	(nc-nc)
Female	3	5.0	nc	(nc-nc)	Testis				
Larynx					Male	4	3.5	nc	(nc-nc)
Male	0	3.6	nc	(nc-nc)	Thyroid				
Female	0	0.9	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Leukemia					Female	9	6.9	130.6	(59.6-247.9)
Male	4	6.1	nc	(nc-nc)	Uteri Corpus and Uterus, NOS				
Female	8	4.9	162.9	(70.1-320.9)	Female	12	15.1	79.3	(40.9-138.5)
Liver and Intrahepatic Bile Ducts					All Sites / Types				
Male	5	3.7	135.2	(43.6-315.5)	Male	272	259.0	105.0	(92.9-118.3)
Female	1	1.3	nc	(nc-nc)	Female	274	240.7	113.8	(100.8-128.2)
Lung and Bronchus									
Male	38	36.8	103.3	(73.1-141.8)					
Female	53	31.5	168.3	(126.0-220.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bladder, Urinary						Melanoma of Skin				
Male	8	8.3	96.6	(41.6-190.3)		Male	2	4.5	nc	(nc-nc)
Female	6	3.0	197.8	(72.2-430.5)		Female	3	3.7	nc	(nc-nc)
Brain and Other Nervous System						Multiple Myeloma				
Male	1	1.8	nc	(nc-nc)		Male	0	1.2	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)		Female	1	1.0	nc	(nc-nc)
Breast						Non-Hodgkin Lymphoma				
Male	1	0.3	nc	(nc-nc)		Male	1	4.4	nc	(nc-nc)
Female	26	33.4	78.0	(50.9-114.2)		Female	4	3.9	nc	(nc-nc)
Cervix Uteri						Oral Cavity & Pharynx				
Female	1	1.7	nc	(nc-nc)		Male	6	3.4	175.7	(64.2-382.5)
Colon / Rectum						Ovary				
Male	12	12.9	92.9	(48.0-162.3)		Female	6	3.4	176.3	(64.4-383.7)
Female	14	12.3	113.6	(62.1-190.7)		Pancreas				
Esophagus						Prostate				
Male	3	2.1	nc	(nc-nc)		Male	2	2.4	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)		Female	3	2.5	nc	(nc-nc)
Hodgkin Lymphoma						Stomach				
Male	0	0.8	nc	(nc-nc)		Male	2	2.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)		Female	2	1.3	nc	(nc-nc)
Kidney & Renal Pelvis						Testis				
Male	1	3.5	nc	(nc-nc)		Male	1	1.5	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)		Thyroid				
Larynx						Thyroid				
Male	1	1.6	nc	(nc-nc)		Male	0	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)						
Leukemia										
Male	6	2.7	218.4	(79.7-475.4)						

Female	2	2.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	2	1.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Lung and Bronchus				
Male	16	16.4	97.7	(55.8-158.7)
Female	25	14.1	177.1	(114.6-261.5)

Female	1	3.0	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	6	6.5	92.7	(33.9-201.8)
All Sites / Types				
Male	103	114.9	89.7	(73.2-108.8)
Female	109	107.3	101.5	(83.4-122.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

354
Winchester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	19	25.9	73.4	(44.2-114.7)
Female	10	10.2	97.9	(46.9-180.1)
Brain and Other Nervous System				
Male	8	4.7	170.5	(73.4-336.1)
Female	3	4.2	nc	(nc-nc)
Breast				
Male	1	0.8	nc	(nc-nc)
Female	106	101.9	104.0	(85.2-125.8)
Cervix Uteri				
Female	2	4.5	nc	(nc-nc)
Colon / Rectum				

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	17	12.7	133.8	(77.9-214.2)
Female	15	10.4	144.4	(80.8-238.3)
Multiple Myeloma				
Male	3	3.6	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	11	12.6	87.5	(43.6-156.6)
Female	10	12.3	81.2	(38.9-149.3)
Oral Cavity & Pharynx				
Male	5	9.7	51.7	(16.7-120.7)
Female	10	5.0	200.7	(96.1-369.2)
Ovary				

Male	35	39.8	87.9	(61.2-122.3)					
Female	50	42.4	117.9	(87.5-155.4)					
Esophagus					Pancreas				
Male	2	6.3	nc	(nc-nc)	Female	11	10.5	105.1	(52.4-188.0)
Female	2	2.1	nc	(nc-nc)	Male	6	7.4	81.0	(29.6-176.4)
Hodgkin Lymphoma					Prostate				
Male	4	1.8	nc	(nc-nc)	Female	9	8.8	102.2	(46.7-194.1)
Female	2	1.6	nc	(nc-nc)	Male	129	106.0	121.7	(101.6-144.6)
Kidney & Renal Pelvis					Stomach				
Male	13	10.1	128.1	(68.2-219.1)	Male	8	6.8	118.2	(50.9-233.0)
Female	8	7.0	114.1	(49.1-224.8)	Female	5	4.6	109.0	(35.1-254.3)
Larynx					Testis				
Male	4	4.6	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Thyroid				
Leukemia					Male	5	2.3	220.1	(70.9-513.7)
Male	7	7.7	90.9	(36.4-187.3)	Female	6	7.4	81.6	(29.8-177.5)
Female	9	7.0	129.1	(58.9-245.2)	Uteri Corpus and Uterus, NOS				
Liver and Intrahepatic Bile Ducts					Female	22	20.0	109.8	(68.8-166.2)
Male	6	4.7	127.1	(46.4-276.7)	All Sites / Types				
Female	1	2.0	nc	(nc-nc)	Male	343	343.1	100.0	(89.7-111.1)
Lung and Bronchus					Female	330	337.3	97.8	(87.6-109.0)
Male	38	50.7	75.0	(53.0-102.9)					
Female	27	45.5	59.3	(39.1-86.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

355
Windsor

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	0	0.9	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	3.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.2	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
					Female	0	0.2	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	0	1.5	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)					
Esophagus					Pancreas				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.1	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	1	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Larynx					Testis				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)

Female	0	0.0	nc	(nc-nc)
Leukemia				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Lung and Bronchus				
Male	0	1.8	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)

Thyroid

Male	0	0.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	0	0.7	nc	(nc-nc)
--------	---	-----	----	---------

All Sites / Types

Male	8	12.8	62.5	(26.9-123.1)
Female	5	10.4	48.0	(15.5-112.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

356

Winthrop

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	27	21.2	127.3	(83.9-185.2)	Male	11	10.5	104.3	(52.0-186.6)
Female	7	8.7	80.7	(32.3-166.3)	Female	11	9.0	122.0	(60.8-218.3)
Brain and Other Nervous System					Multiple Myeloma				
Male	6	3.9	155.6	(56.8-338.7)	Male	3	2.9	nc	(nc-nc)
Female	7	3.6	195.6	(78.4-403.1)	Female	2	2.7	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.6	nc	(nc-nc)	Male	9	10.4	86.2	(39.3-163.6)
Female	85	85.1	99.8	(79.7-123.5)	Female	15	10.6	141.8	(79.3-233.9)
Cervix Uteri					Oral Cavity & Pharynx				

						Male	8	7.8	103.0	(44.3-202.9)
	Female	4	3.9	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
Colon / Rectum						Ovary				
	Male	38	32.6	116.7	(82.6-160.2)					
	Female	51	36.0	141.6	(105.4-186.2)	Female	14	8.8	159.2	(87.0-267.2)
Esophagus						Pancreas				
	Male	4	5.0	nc	(nc-nc)	Male	7	6.0	115.9	(46.4-238.8)
	Female	0	1.8	nc	(nc-nc)	Female	9	7.5	120.1	(54.8-228.1)
Hodgkin Lymphoma						Prostate				
	Male	2	1.7	nc	(nc-nc)	Male	93	83.8	110.9	(89.5-135.9)
	Female	0	1.5	nc	(nc-nc)					
Kidney & Renal Pelvis						Stomach				
	Male	12	8.2	146.7	(75.7-256.3)	Male	3	5.6	nc	(nc-nc)
	Female	5	5.9	84.2	(27.1-196.5)	Female	3	3.9	nc	(nc-nc)
Larynx						Testis				
	Male	3	3.7	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
	Female	2	1.0	nc	(nc-nc)					
Leukemia						Thyroid				
	Male	5	6.3	79.2	(25.5-184.7)	Male	2	2.0	nc	(nc-nc)
	Female	7	5.8	119.7	(47.9-246.6)	Female	8	6.6	121.3	(52.2-239.0)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
	Male	4	3.8	nc	(nc-nc)					
	Female	2	1.7	nc	(nc-nc)	Female	20	16.6	120.6	(73.6-186.2)
Lung and Bronchus						All Sites / Types				
	Male	40	40.9	97.7	(69.8-133.0)	Male	298	278.4	107.0	(95.2-119.9)
	Female	48	38.8	123.8	(91.2-164.1)	Female	330	285.3	115.7	(103.5-128.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

357

Woburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	33	40.2	82.1	(56.5-115.3)	Male	25	20.6	121.3	(78.5-179.1)
Female	18	15.4	116.6	(69.1-184.3)	Female	13	16.9	76.8	(40.8-131.3)
Brain and Other Nervous System					Multiple Myeloma				
Male	7	7.8	89.4	(35.8-184.2)	Male	6	5.6	107.4	(39.2-233.8)
Female	8	6.7	119.1	(51.3-234.8)	Female	4	4.8	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	1.2	nc	(nc-nc)	Male	26	20.3	128.0	(83.6-187.5)
Female	168	157.7	106.5	(91.0-123.9)	Female	23	19.2	119.9	(76.0-179.9)
Cervix Uteri					Oral Cavity & Pharynx				
Female	7	7.4	94.0	(37.6-193.6)	Male	17	15.1	112.7	(65.6-180.5)
Colon / Rectum					Female	7	7.7	90.4	(36.2-186.3)
Male	56	62.0	90.4	(68.3-117.4)	Ovary				
Female	64	62.1	103.1	(79.4-131.7)	Female	15	16.1	92.9	(52.0-153.2)
Esophagus					Pancreas				
Male	9	9.8	92.3	(42.1-175.2)	Male	10	11.5	87.3	(41.8-160.6)
Female	2	3.0	nc	(nc-nc)	Female	15	13.0	115.4	(64.5-190.3)
Hodgkin Lymphoma					Prostate				
Male	6	3.6	166.6	(60.8-362.7)	Male	132	167.4	78.9	(66.0-93.5)
Female	2	3.0	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	10	10.4	96.1	(46.0-176.7)
Male	15	16.0	93.7	(52.4-154.5)					

Larynx	Female	5	11.0	45.4	(14.6-105.9)	Testis	Female	8	6.5	122.5	(52.8-241.5)
	Male	3	7.2	nc	(nc-nc)		Male	5	6.7	75.1	(24.2-175.2)
Leukemia	Female	1	2.0	nc	(nc-nc)	Thyroid	Male	4	4.1	nc	(nc-nc)
	Male	15	12.3	121.5	(67.9-200.4)		Female	14	12.8	109.0	(59.5-182.9)
	Female	14	10.5	133.4	(72.9-223.8)	Uteri Corpus and Uterus, NOS	Female	33	31.3	105.5	(72.6-148.1)
Liver and Intrahepatic Bile Ducts	Male	6	7.4	81.0	(29.6-176.3)	All Sites / Types	Male	495	544.0	91.0	(83.1-99.4)
	Female	2	2.9	nc	(nc-nc)		Female	558	520.1	107.3	(98.6-116.6)
Lung and Bronchus	Male	81	80.0	101.2	(80.4-125.8)						
	Female	81	72.2	112.3	(89.1-139.5)						

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

358
Worcester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	167	171.1	97.6	(83.4-113.6)	Male	53	84.8	62.5	(46.8-81.8)
Female	62	70.3	88.2	(67.6-113.1)	Female	36	73.0	49.3	(34.5-68.3)
Brain and Other Nervous System					Multiple Myeloma				
Male	21	32.8	63.9	(39.6-97.7)	Male	24	23.4	102.5	(65.6-152.5)
Female	30	30.2	99.5	(67.1-142.0)	Female	24	21.9	109.7	(70.2-163.2)
Breast					Non-Hodgkin Lymphoma				

Male	5	5.0	100.6	(32.4-234.7)	Male	95	85.3	111.4	(90.1-136.2)
Female	548	669.9	81.8	(75.1-88.9)	Female	90	86.3	104.3	(83.9-128.2)
Cervix Uteri					Oral Cavity & Pharynx				
Female	33	31.1	106.2	(73.1-149.1)	Male	57	60.4	94.4	(71.5-122.3)
Colon / Rectum					Female	37	33.7	109.8	(77.3-151.4)
Male	223	261.4	85.3	(74.5-97.3)	Ovary				
Female	264	293.5	90.0	(79.4-101.5)	Female	67	70.3	95.3	(73.9-121.1)
Esophagus					Pancreas				
Male	39	39.5	98.7	(70.2-135.0)	Male	54	48.2	111.9	(84.1-146.1)
Female	12	14.3	84.1	(43.4-146.9)	Female	63	61.0	103.3	(79.3-132.1)
Hodgkin Lymphoma					Prostate				
Male	10	15.9	63.0	(30.2-115.9)	Male	477	654.7	72.9	(66.5-79.7)
Female	12	14.2	84.7	(43.7-147.9)	Stomach				
Kidney & Renal Pelvis					Male	34	44.9	75.7	(52.4-105.8)
Male	65	64.5	100.7	(77.7-128.4)	Female	32	31.7	101.0	(69.1-142.6)
Female	56	47.9	117.0	(88.4-152.0)	Testis				
Larynx					Male	32	28.2	113.6	(77.7-160.4)
Male	24	28.9	83.0	(53.2-123.5)	Thyroid				
Female	11	8.3	132.8	(66.2-237.6)	Male	10	16.2	61.7	(29.5-113.5)
Leukemia					Female	38	54.4	69.9	(49.5-96.0)
Male	59	53.2	110.9	(84.4-143.0)	Uteri Corpus and Uterus, NOS				
Female	47	49.3	95.4	(70.1-126.9)	Female	135	130.5	103.5	(86.8-122.5)
Liver and Intrahepatic Bile Ducts					All Sites / Types				
Male	43	30.0	143.1	(103.6-192.8)	Male	1988	2226.7	89.3	(85.4-93.3)
Female	14	13.7	102.1	(55.7-171.2)	Female	2082	2294.7	90.7	(86.9-94.7)
Lung and Bronchus									
Male	348	326.7	106.5	(95.6-118.3)					
Female	300	312.6	96.0	(85.4-107.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

359

Worthington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	4	1.5	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	3	5.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	0.3	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Colon / Rectum					Female	0	0.2	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	Ovary				
Female	0	1.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.1	nc	(nc-nc)	Male	15	6.1	246.5	(137.9-406.6)
Female	0	0.1	nc	(nc-nc)					

Kidney & Renal Pelvis						Stomach					
Male	1	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)		
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)		
Larynx						Testis					
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)		
Female	0	0.1	nc	(nc-nc)							
Leukemia						Thyroid					
Male	0	0.5	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)		
Female	0	0.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)		
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
Male	0	0.3	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)		
Female	0	0.1	nc	(nc-nc)							
Lung and Bronchus						All Sites / Types					
Male	0	2.9	nc	(nc-nc)	Male	24	19.9	120.6	(77.2-179.4)		
Female	0	2.1	nc	(nc-nc)	Female	5	16.3	30.7	(9.9-71.6)		

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

360
Wrentham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	8	9.2	87.0	(37.5-171.5)	Male	8	5.3	151.5	(65.2-298.5)
Female	8	3.7	216.3	(93.1-426.3)	Female	5	4.4	113.3	(36.5-264.4)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	2.1	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)

Male	23	18.1	127.1	(80.5-190.7)
Female	10	16.6	60.2	(28.8-110.7)

Male	127	129.2	98.3	(82.0-117.0)
Female	126	131.1	96.1	(80.1-114.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

361
Yarmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	62	50.1	123.7	(94.8-158.6)	Male	40	20.6	194.0	(138.6-264.2)
Female	27	18.6	144.9	(95.4-210.8)	Female	29	15.2	191.0	(127.9-274.3)
Brain and Other Nervous System					Multiple Myeloma				
Male	11	6.9	159.7	(79.6-285.8)	Male	7	6.6	106.2	(42.6-218.9)
Female	6	6.4	93.9	(34.3-204.3)	Female	3	5.8	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	3	1.3	nc	(nc-nc)	Male	29	21.4	135.8	(90.9-195.0)
Female	179	156.7	114.2	(98.1-132.3)	Female	22	21.3	103.2	(64.6-156.2)
Cervix Uteri					Oral Cavity & Pharynx				
Female	6	5.9	101.5	(37.1-221.0)	Male	10	14.7	68.0	(32.6-125.2)
Colon / Rectum					Female	6	8.2	73.5	(26.8-159.9)
Male	73	74.9	97.5	(76.4-122.6)	Ovary				
Female	78	78.2	99.7	(78.8-124.4)	Female	18	16.5	108.9	(64.5-172.1)
Esophagus					Pancreas				
Male	13	10.8	120.3	(64.0-205.8)	Male	13	13.7	94.9	(50.5-162.3)
Female	5	3.8	131.2	(42.3-306.3)	Female	17	16.5	103.3	(60.1-165.3)

Hodgkin Lymphoma					Prostate				
Male	5	2.3	222.2	(71.6-518.5)	Male	237	182.0	130.2	(114.2-147.9)
Female	1	2.1	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	16	16.5	96.7	(55.2-157.1)	Male	16	12.8	124.6	(71.2-202.4)
Female	15	11.9	126.0	(70.5-207.9)	Female	5	8.4	59.2	(19.1-138.2)
Larynx					Testis				
Male	8	7.7	104.0	(44.8-204.9)	Male	3	3.0	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)					
Leukemia					Thyroid				
Male	13	13.2	98.2	(52.2-167.9)	Male	0	2.9	nc	(nc-nc)
Female	14	11.6	120.8	(66.0-202.7)	Female	4	8.8	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	6	7.7	77.9	(28.5-169.6)					
Female	1	3.6	nc	(nc-nc)	Female	33	31.4	104.9	(72.2-147.4)
Lung and Bronchus					All Sites / Types				
Male	102	93.4	109.2	(89.0-132.5)	Male	713	603.5	118.1	(109.6-127.1)
Female	94	81.7	115.0	(93.0-140.8)	Female	607	559.8	108.4	(100.0-117.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;